Who are Atacand/HCT, Caduet's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atacand-hct-caduet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Atacand/HCT, Caduet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atacand/HCT, Caduet (Atacand/HCT, Caduet) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker/thiazide diuretic combination (Atacand/HCT); Calcium channel blocker/HMG-CoA reductase inhibitor combination (Caduet). Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker/thiazide diuretic combination (Atacand/HCT); Calcium channel blocker/HMG-CoA reductase inhibitor combination (Caduet) Angiotensin II type 1 receptor, thiazide-sensitive sodium-chloride cotransporter (Atacand/HCT); L-type calcium channel, HMG-CoA reductase (Caduet) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Atacand/HCT, Caduet (Atacand/HCT, Caduet) — Baim Institute for Clinical Research. Atacand/HCT combines an angiotensin II receptor blocker with a thiazide diuretic to reduce blood pressure through vasodilation and sodium/fluid excretion, while Caduet combines an HMG-CoA reductase inhibitor with a calcium channel blocker to lower cholesterol and blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atacand/HCT, Caduet TARGET	Atacand/HCT, Caduet	Baim Institute for Clinical Research	phase 3	Angiotensin II receptor blocker/thiazide diuretic combination (Atacand/HCT); Calcium channel blocker/HMG-CoA reductase inhibitor combination (Caduet)	Angiotensin II type 1 receptor, thiazide-sensitive sodium-chloride cotransporter (Atacand/HCT); L-type calcium channel, HMG-CoA reductase (Caduet)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker/thiazide diuretic combination (Atacand/HCT); Calcium channel blocker/HMG-CoA reductase inhibitor combination (Caduet) class)

Baim Institute for Clinical Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atacand/HCT, Caduet — Competitive Intelligence Brief. https://druglandscape.com/ci/atacand-hct-caduet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab